Physician profile
Nancy Popps
NPI 1164186961
$1,115.37
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.14 · 2022: $593 · 2023: $380 · 2024: $53.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.08 | 2022-2024 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $139.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.00 | 2022-2023 | Xifaxan, Trulance |
| Abbvie INC. | $91.77 | 2023 | |
| Lilly USA, LLC | $75.72 | 2022-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $72.78 | 2022 | |
| Almatica Pharma LLC | $59.73 | 2021 | |
| Jazz Pharmaceuticals INC. | $52.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $52.70 | 2021-2022 | |
| Pfizer INC. | $49.44 | 2023 | |
| Shield Therapeutics INC | $28.38 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $27.31 | 2021-2022 | |
| Seqirus USA INC | $19.91 | 2024 | Flucelvax, Fluad |
| Dynavax Technologies Corporation | $18.45 | 2023 | Heplisav-B |
| Gilead Sciences, INC. | $18.29 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.60 | 2022 | |
| Grifols USA, LLC | $17.34 | 2023 | Prolastin-C Liquid |
| Amgen INC. | $17.02 | 2023 | Evenity, Prolia |
| Exact Sciences Corporation | $15.52 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.91 | 2022 | |
| Inogen, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Popps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.